-
1
-
-
0024454042
-
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer
-
Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317, 1989.
-
(1989)
J Clin Oncol
, vol.7
, pp. 1310-1317
-
-
Preusser, P.1
Wilke, H.2
Achterrath, W.3
Fink, U.4
Lenaz, L.5
Heinicke, A.6
Meyer, J.7
Meyer, H.J.8
Buente, H.9
-
2
-
-
0028032976
-
Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer; a prospective randomized trial of the Italian oncology group for clinical research
-
Cocconi G, Bella M, Zironi S, Algeri R, Costanzo FD, Lisi VD, Luppi G, Mazzocchi B, Rodino C, Soldani M, Gilli G and Finard C: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer; A prospective randomized trial of the Italian oncology group for clinical research. J Clin Oncol 12: 2687-2693, 1994.
-
(1994)
J Clin Oncol
, vol.12
, pp. 2687-2693
-
-
Cocconi, G.1
Bella, M.2
Zironi, S.3
Algeri, R.4
Costanzo, F.D.5
Lisi, V.D.6
Luppi, G.7
Mazzocchi, B.8
Rodino, C.9
Soldani, M.10
Gilli, G.11
Finard, C.12
-
3
-
-
0018931354
-
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastrric cancer
-
Macdonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht, C, Brunet R and Lagarde C: 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastrric cancer. Ann Intern Med 93: 533-536, 1980.
-
(1980)
Ann Intern Med
, vol.93
, pp. 533-536
-
-
Macdonald, J.S.1
Schein, P.S.2
Wooley, P.V.3
Smythe, T.4
Ueno, W.5
Hoth, D.6
Smith, F.7
Boiron, M.8
Gisselbrecht, C.9
Brunet, R.10
Lagarde, C.11
-
4
-
-
0020955894
-
High dose MTX/5-Fu and adriamycin for gastric cancer
-
Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H and Gross R: High dose MTX/5-Fu and adriamycin for gastric cancer. Sem Oncol 10: 29-31, 1983.
-
(1983)
Sem Oncol
, vol.10
, pp. 29-31
-
-
Klein, H.O.1
Wickramanayake, P.D.2
Dieterle, F.3
Mohr, R.4
Oerkermann, H.5
Gross, R.6
-
5
-
-
0028016155
-
A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF)
-
Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N and Ford H: A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). Ann Oncol 5: 609-616, 1994.
-
(1994)
Ann Oncol
, vol.5
, pp. 609-616
-
-
Findlay, M.1
Cunningham, D.2
Norman, A.3
Mansi, J.4
Nicolson, M.5
Hickish, T.6
Nicolson, V.7
Nash, A.8
Sacks, N.9
Ford, H.10
-
6
-
-
0023726563
-
Report on nationalwide pooled data and cohort investigation in UFT Phase II study
-
Oka K, Taguchi T and Kimura K: Report on nationalwide pooled data and cohort investigation in UFT Phase II study. Cancer Chemother Pharmacol 22: 333-338, 1988.
-
(1988)
Cancer Chemother Pharmacol
, vol.22
, pp. 333-338
-
-
Oka, K.1
Taguchi, T.2
Kimura, K.3
-
7
-
-
9344248389
-
Antitumor activity of 1M tegafur - 0.4 M 5-chloro-2,4- dihydroxypyrimidine- 1 M potasium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
-
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1M tegafur - 0.4 M 5-chloro-2,4-dihydroxypyrimidine- 1 M potasium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
-
(1996)
Cancer Res
, vol.56
, pp. 2602-2606
-
-
Shirasaka, T.1
Nakano, K.2
Takechi, T.3
Satake, H.4
Uchida, J.5
Fujioka, A.6
Saito, H.7
Oyama, K.8
Takeda, S.9
Unemi, N.10
Fukushima, M.11
-
8
-
-
11544323426
-
Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts
-
Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimoto H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
-
(1998)
Int J Oncol
, vol.13
, pp. 693-698
-
-
Fukushima, M.1
Satake, H.2
Uchida, J.3
Shimamoto, Y.4
Kato, T.5
Takechi, T.6
Okabe, H.7
Fujioka, A.8
Nakano, K.9
Ohshimoto, H.10
Takeda, S.11
Shirasaka, T.12
-
9
-
-
0032819756
-
The S-1 Gastrointestinal Cancer Study Group: An early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers
-
Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y and Taguchi T, The S-1 Gastrointestinal Cancer Study Group: An early phase II study of oral S-1, a newly developed 5-fluoruracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57: 202-210, 1999.
-
(1999)
Oncology
, vol.57
, pp. 202-210
-
-
Sugimachi, K.1
Maehara, Y.2
Horikoshi, N.3
Shimada, Y.4
Sakata, Y.5
Taguchi, T.6
-
10
-
-
0032189218
-
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat - 1 M otastat potasium) in advanced gastric cancer patients
-
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M Gimestat - 1 M otastat potasium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
-
(1998)
Eur J Cancer
, vol.34
, pp. 1715-1720
-
-
Sakata, Y.1
Ohtsu, A.2
Horikoshi, N.3
Sugimachi, K.4
Mitachi, Y.5
Taguchi, T.6
-
11
-
-
6544263262
-
Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug
-
Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizaka H, Yamada Y, Uno S, Taguchi T and Shirasaka T: Pharmakokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5: 2000-2005, 1999.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2000-2005
-
-
Hirata, K.1
Horikoshi, N.2
Aiba, K.3
Okazaki, M.4
Denno, R.5
Sasaki, K.6
Nakano, Y.7
Ishizaka, H.8
Yamada, Y.9
Uno, S.10
Taguchi, T.11
Shirasaka, T.12
-
12
-
-
0034029776
-
The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer
-
Koizumi W, Kurihara M, Nakano S and Hasegawa K: The S-1 gastrointestinal cancer study group: Phase II study of S-1, a novel derivative 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000.
-
(2000)
Oncology
, vol.58
, pp. 191-197
-
-
Koizumi, W.1
Kurihara, M.2
Nakano, S.3
Hasegawa, K.4
-
13
-
-
0037570623
-
S-1 in gastric cancer: A comprehensive review
-
Maehara Y: S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6 (Suppl 1): 2-8, 2003.
-
(2003)
Gastric Cancer
, vol.6
, Issue.SUPPL. 1
, pp. 2-8
-
-
Maehara, Y.1
-
14
-
-
0026428123
-
Studies with RP56976 (Taxotere): A semisynthetic analogue of taxol
-
Ringel I and Horwitz B: Studies with RP56976 (Taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 288-291
-
-
Ringel, I.1
Horwitz, B.2
-
15
-
-
0026667555
-
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
-
Kelland LR and Abel G: Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444-450, 1992.
-
(1992)
Cancer Chemother Pharmacol
, vol.30
, pp. 444-450
-
-
Kelland, L.R.1
Abel, G.2
-
16
-
-
0026688488
-
Effects of taxotere on murine and human tumor cell lines
-
Riou JF, Naudin A and Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187: 164-170, 1992.
-
(1992)
Biochem Biophys Res Commun
, vol.187
, pp. 164-170
-
-
Riou, J.F.1
Naudin, A.2
Lavelle, F.3
-
17
-
-
0026425674
-
Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue
-
Bissery MC, Guenard D, Vogelein G and Lavelle F: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991.
-
(1991)
Cancer Res
, vol.51
, pp. 4845-4852
-
-
Bissery, M.C.1
Guenard, D.2
Vogelein, G.3
Lavelle, F.4
-
18
-
-
0027516128
-
Phase I and pharmacokinetic study of Taxotere(RP56976, NSC 628503) given as a short intravenous infusion
-
Extra JM, Rousseau F, Bruno R et al: Phase I and pharmacokinetic study of Taxotere(RP56976, NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042, 1993.
-
(1993)
Cancer Res
, vol.53
, pp. 1037-1042
-
-
Extra, J.M.1
Rousseau, F.2
Bruno, R.3
-
19
-
-
0002129338
-
Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation of Taxotere
-
abstr 208
-
Aapro MS, Zullian G, Alberto P et al: Phase I and pharmacokinetic study of RP56976 in a new ethanol free formulation of Taxotere. Ann Oncol 3: 53, (suppl 5, abstr 208), 1992.
-
(1992)
Ann Oncol
, vol.3
, Issue.SUPPL. 5
, pp. 53
-
-
Aapro, M.S.1
Zullian, G.2
Alberto, P.3
-
20
-
-
0027211031
-
Phase I clinical trial of Taxotere administered as either 2-hour or 6-hour intravenous infusion
-
Burris H, Irvin R, Kuhn J et al: Phase I clinical trial of Taxotere administered as either 2-hour or 6-hour intravenous infusion. J Clin Oncol 11: 950-958, 1993.
-
(1993)
J Clin Oncol
, vol.11
, pp. 950-958
-
-
Burris, H.1
Irvin, R.2
Kuhn, J.3
-
21
-
-
0026471026
-
Phase I trial of Taxotere: Five-day schedule
-
Pazdur R, Newman RA, Newman B et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84: 1781-1788, 1992.
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 1781-1788
-
-
Pazdur, R.1
Newman, R.A.2
Newman, B.3
-
22
-
-
0027512095
-
Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion
-
Bissett D, Setanoians A, Cassidy J et al: Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 53: 523-527, 1993.
-
(1993)
Cancer Res
, vol.53
, pp. 523-527
-
-
Bissett, D.1
Setanoians, A.2
Cassidy, J.3
-
23
-
-
0028291647
-
Phase I study of docetaxel administered as 1-hour intravenous infusion on a week basis
-
Tomiak E, Piccart MJ, Kerger J et al: Phase I study of docetaxel administered as 1-hour intravenous infusion on a week basis. J Clin Oncol 12: 1458-1467, 1994.
-
(1994)
J Clin Oncol
, vol.12
, pp. 1458-1467
-
-
Tomiak, E.1
Piccart, M.J.2
Kerger, J.3
-
24
-
-
0028130156
-
An early phase II clinical study of RP 56976 (Docetaxel) in patients with cancer of the gastrointestinal tract
-
in Japanese
-
Taguchi T: An early phase II clinical study of RP 56976 (Docetaxel) in patients with cancer of the gastrointestinal tract. Jpn J Cancer Chemother 26: 2431-2437, 1994. (in Japanese)
-
(1994)
Jpn J Cancer Chemother
, vol.26
, pp. 2431-2437
-
-
Taguchi, T.1
-
25
-
-
18144450345
-
Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese cooperative study group trial (Group A)
-
Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J and Hirabayashi N: Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese cooperative study group trial (Group A). Jpn J Cancer Chemother 25: 1915-1924, 1998.
-
(1998)
Jpn J Cancer Chemother
, vol.25
, pp. 1915-1924
-
-
Taguchi, T.1
Sakata, Y.2
Kanamaru, R.3
Kurihara, M.4
Suminaga, M.5
Ota, J.6
Hirabayashi, N.7
-
26
-
-
2342465869
-
A late phase II clinical study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (Group B)
-
Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T and Furue H: A late phase II clinical study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (Group B). Jpn J Cancer Chemother 26: 487-496, 1999.
-
(1999)
Jpn J Cancer Chemother
, vol.26
, pp. 487-496
-
-
Mai, M.1
Sakata, Y.2
Kanamaru, R.3
Kurihara, M.4
Suminaga, M.5
Ota, J.6
Hirabayashi, N.7
Taguchi, T.8
Furue, H.9
-
27
-
-
0028487470
-
Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial
-
Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders KJ, Franklin H, LeBail N and Verwij J for the EPRTC Clinical Trial Group: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383, 1994.
-
(1994)
Br J Cancer
, vol.70
, pp. 380-383
-
-
Sulkes, A.1
Smyth, J.2
Sessa, C.3
Dirix, L.Y.4
Vermorken, J.B.5
Kaye, S.6
Wanders, K.J.7
Franklin, H.8
LeBail, N.9
Verwij, J.10
-
28
-
-
0034830598
-
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction
-
Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction. Ann Oncol 12: 1133-1137, 2001.
-
(2001)
Ann Oncol
, vol.12
, pp. 1133-1137
-
-
Yamada, Y.1
Shirao, K.2
Ohtsu, A.3
Boku, N.4
Hyodo, I.5
Saitoh, H.6
Miyata, Y.7
Taguchi, T.8
-
29
-
-
0034856122
-
Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: Effects on mouse mammary tumor cell line MM2 in vitro and in vivo
-
Takeda Y, Yoshizaki I, Nonaka Y, Yanagie H, Matsuzawa A and Eriguchi M: Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anti-Cancer Drugs 12: 691-698, 2001.
-
(2001)
Anti-Cancer Drugs
, vol.12
, pp. 691-698
-
-
Takeda, Y.1
Yoshizaki, I.2
Nonaka, Y.3
Yanagie, H.4
Matsuzawa, A.5
Eriguchi, M.6
-
31
-
-
0026439301
-
Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method
-
Verginol JC, Bruno R, Montay G and Frydman A: Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582: 273-278, 1992.
-
(1992)
J Chromatogr
, vol.582
, pp. 273-278
-
-
Verginol, J.C.1
Bruno, R.2
Montay, G.3
Frydman, A.4
-
32
-
-
0028034350
-
Phase I clinical trial of RP56976 (Docetaxel) a new anticancer drug
-
Taguchi T, Furue H, Niitani H, Ishitani K, Ariyoshi Y, Noda K, Furuse K, Fukuoka M, Yakushiji M and Kashimura M: Phase I clinical trial of RP56976 (Docetaxel) a new anticancer drug. Jpn J Cancer Chemother 21: 1997-2005, 1994.
-
(1994)
Jpn J Cancer Chemother
, vol.21
, pp. 1997-2005
-
-
Taguchi, T.1
Furue, H.2
Niitani, H.3
Ishitani, K.4
Ariyoshi, Y.5
Noda, K.6
Furuse, K.7
Fukuoka, M.8
Yakushiji, M.9
Kashimura, M.10
-
33
-
-
0022448330
-
Distribution and inhibition of dihydropyrimidine dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
-
Ho DH, Townsend L, Luna MA and Body GP: Distribution and inhibition of dihydropyrimidine dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 6: 781-784, 1986.
-
(1986)
Anticancer Res
, vol.6
, pp. 781-784
-
-
Ho, D.H.1
Townsend, L.2
Luna, M.A.3
Body, G.P.4
-
34
-
-
0030853620
-
Enhancing 5-fluorouracil cytotoxcity by inhibiing dihydropyrimidine dehydrogenase activity with uracil in human tumor cells
-
Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxcity by inhibiing dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997.
-
(1997)
Int J Oncol
, vol.11
, pp. 1041-1044
-
-
Takechi, T.1
Uchida, J.2
Fujioka, A.3
Fukushima, M.4
-
35
-
-
0037908626
-
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activity in gastric cancer
-
Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T, Yonezawa, H, Oyama K, Saito K, Kanzaka N, Ohtani S, Nemoto T, Hoshino Y, Kogure M and Gotoh M: Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activity in gastric cancer. Gastric Cancer 6 (Suppl 1): 71-81, 2003.
-
(2003)
Gastric Cancer
, vol.6
, Issue.SUPPL. 1
, pp. 71-81
-
-
Terashima, M.1
Fujiwara, H.2
Takagane, A.3
Abe, K.4
Irinoda, T.5
Nakaya, T.6
Yonezawa, H.7
Oyama, K.8
Saito, K.9
Kanzaka, N.10
Ohtani, S.11
Nemoto, T.12
Hoshino, Y.13
Kogure, M.14
Gotoh, M.15
-
36
-
-
0037908625
-
Future prospects of personalized chemotherapy in gastric cancer patients: Results of a prospective randomized pilot study
-
Yoshida K, Tanabe K, Ueno H, Ohta K, Hihara J, Toge T and Nishiyama M: Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 6 (Suppl 1): 82-89, 2003.
-
(2003)
Gastric Cancer
, vol.6
, Issue.SUPPL. 1
, pp. 82-89
-
-
Yoshida, K.1
Tanabe, K.2
Ueno, H.3
Ohta, K.4
Hihara, J.5
Toge, T.6
Nishiyama, M.7
-
37
-
-
0030975059
-
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma
-
Chung Y, Yamashita Y, Matsuoka T, Nakata T, Onoda T, Maeda K, Sawada K, Kato Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80: 1-7, 1997.
-
(1997)
Cancer
, vol.80
, pp. 1-7
-
-
Chung, Y.1
Yamashita, Y.2
Matsuoka, T.3
Nakata, T.4
Onoda, T.5
Maeda, K.6
Sawada, K.7
Kato, Y.8
Shirasaka, T.9
Sowa, M.10
-
38
-
-
0034524342
-
An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer
-
Kim R, Nishimoto N, Inoue H, Yoshida K and Toge T: An analysis of the therapeutic efficacy of protracted infusion of low-dose 5-fluorouracil and cisplatin in advanced gastric cancer. J Infect Chemother 6: 222-228, 2000.
-
(2000)
J Infect Chemother
, vol.6
, pp. 222-228
-
-
Kim, R.1
Nishimoto, N.2
Inoue, H.3
Yoshida, K.4
Toge, T.5
-
39
-
-
0019424961
-
The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L 1210 cells
-
Cadman E, Heiner R and Benz C: The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 25: 1695-704,1981.
-
(1981)
J Biol Chem
, vol.25
, pp. 1695-1704
-
-
Cadman, E.1
Heiner, R.2
Benz, C.3
-
40
-
-
0038246284
-
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer
-
Mori T, Fujiwara Y, Yano M, Tamura S, Yasuda T, Takiguchi S and Monden M: Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer. Gastric Cancer 6 (Suppl 1): 13-18, 2003.
-
(2003)
Gastric Cancer
, vol.6
, Issue.SUPPL. 1
, pp. 13-18
-
-
Mori, T.1
Fujiwara, Y.2
Yano, M.3
Tamura, S.4
Yasuda, T.5
Takiguchi, S.6
Monden, M.7
-
41
-
-
17544396057
-
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer
-
Ando M, Watanabe T, Sasaki Y, Ying DF, Omuro Y, Katsumata N, Narabayashi M, Tokue Y, Fujii, H, Igarashi T, Wakita H, Ohtsu T, Adachi I and Taguchi T: A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 77: 1937-1943, 1998.
-
(1998)
Br J Cancer
, vol.77
, pp. 1937-1943
-
-
Ando, M.1
Watanabe, T.2
Sasaki, Y.3
Ying, D.F.4
Omuro, Y.5
Katsumata, N.6
Narabayashi, M.7
Tokue, Y.8
Fujii, H.9
Igarashi, T.10
Wakita, H.11
Ohtsu, T.12
Adachi, I.13
Taguchi, T.14
-
42
-
-
0032996302
-
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies
-
Peitit T, Aylesworth C, Burris H, Ravdin P, Rodriguez G, Smith L, Peacock N, Smetzer L, Bellet R, von Hoff DD and Rowinsky EK: A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol 10: 223-239, 1999.
-
(1999)
Ann Oncol
, vol.10
, pp. 223-239
-
-
Peitit, T.1
Aylesworth, C.2
Burris, H.3
Ravdin, P.4
Rodriguez, G.5
Smith, L.6
Peacock, N.7
Smetzer, L.8
Bellet, R.9
Von Hoff, D.D.10
Rowinsky, E.K.11
-
43
-
-
0033933427
-
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck
-
Colevas AD, Adak S, Amerin PC, Barton JJ, Costello R and Poner MR: A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann Oncol 11: 535539, 2000.
-
(2000)
Ann Oncol
, vol.11
, pp. 535539
-
-
Colevas, A.D.1
Adak, S.2
Amerin, P.C.3
Barton, J.J.4
Costello, R.5
Poner, M.R.6
-
44
-
-
0034154069
-
Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma
-
Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Hermann R, Honegger H, Cavilli F, Alberto P, Castiglione M and Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Ann Oncol 11: 301-306, 2000.
-
(2000)
Ann Oncol
, vol.11
, pp. 301-306
-
-
Roth, A.D.1
Maibach, R.2
Martinelli, G.3
Fazio, N.4
Aapro, M.S.5
Pagani, O.6
Morant, R.7
Borner, M.M.8
Hermann, R.9
Honegger, H.10
Cavilli, F.11
Alberto, P.12
Castiglione, M.13
Goldhirsch, A.14
|